{"nctId":"NCT02694328","briefTitle":"A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)","startDateStruct":{"date":"2016-03-02","type":"ACTUAL"},"conditions":["Schizophrenia"],"count":561,"armGroups":[{"label":"ALKS 3831","type":"EXPERIMENTAL","interventionNames":["Drug: ALKS 3831"]},{"label":"Olanzapine","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Olanzapine"]}],"interventions":[{"name":"ALKS 3831","otherNames":[]},{"name":"Olanzapine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject has a body mass index (BMI) of 18.0-30.0 kg/m\\^2, inclusive, at Visit 1 and Visit 2\n* Subject meets the DSM-5 criteria for a primary diagnosis of schizophrenia\n* Subject is appropriate for outpatient treatment; has no hospitalizations for acute exacerbations of schizophrenia within 6 months before Visit 1\n* Subject has maintained a stable body weight (change \\</= 5%) for at least 3 months prior to Visit 1 based on self-report\n* Additional criteria may apply\n\nExclusion Criteria:\n\n* Subject has any of the following psychiatric conditions per DSM-5 criteria:\n* Diagnosis of schizoaffective disorder or bipolar I or II disorder, or current, untreated or unstable major depressive disorder\n* Clinically significant cognitive difficulties present within the past 2 years that could interfere with participation in the study\n* Drug-induced or toxic psychosis\n* Any other psychiatric condition that could interfere with participation in the study\n* Subject poses a current suicide risk at Visit 1 or Visit 2 in the opinion of the investigator\n* Subject has inflammatory bowel disease or any other gastrointestinal disorder associated with weight loss, anorexia nervosa, or binge eating disorder\n* Additional criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"55 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in Body Weight at Week 24","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.59","spread":"0.668"},{"groupId":"OG001","value":"4.21","spread":"0.681"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With >/= 10% Weight Gain at Week 24","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.8","spread":null},{"groupId":"OG001","value":"17.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With >/= 7% Weight Gain at Week 24","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.7","spread":null},{"groupId":"OG001","value":"27.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Experiencing of Adverse Events (AEs)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"227","spread":null},{"groupId":"OG001","value":"203","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":276},"commonTop":["Weight increased","Somnolence","Increased appetite","Dry mouth","Waist circumference increased"]}}}